- Senior Investigator, Molecular Structure Section
Dr. Berger earned his B.S. in chemistry from City College of the City University of New York in 1968. He received his Ph.D. in biochemistry and molecular biology in 1973 from Cornell University. He went on to do a postdoctoral fellowship in the department of genetics, biochemistry, and neurobiology at Stanford University School of Medicine from 1973 to 1976 and another fellowship in the department of cellular and developmental immunology at Scripps Clinical and Research Foundation from 1976 to 1977. He was a staff scientist with the Cell Biology Group at the Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts, from 1977 to 1987. He joined the NIAID Laboratory of Viral Diseases in 1987 and became chief of the Molecular Structure Section in 1995.
American Academy of Microbiology Fellow; Bernard Fields Memorial Lectureship, CROI 2007;1st NIH World AIDS Day Award 2006; ISI Highly Cited Researcher, Breakthrough of the Year, Science 1996; AAAS-Newcomb Cleveland Prize 1997; Great Experiments; Kenneth Fong/Clontech Award; Novartis-Drew Award for Biomedical Science; Damon Runyon-Walter Winchell Foundation Most Prominent Alumni; AMA/NIAID Nathan Davis Award; NIH Outstanding Contributions to Education of Postbaccalaureate Trainees; Norman P Salzman Memorial Mentor Award in Virology, Honorable Mention
National Institutes of Health Interest Group Memberships
Virology Interest Group, Immunology Interest Group, Antibody Interest Group, Viral Hepatitis Interest Group
- (2020). A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region. Frontiers in Cellular and Infection Microbiology. 10,
- (2018). Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. Cell Host & Microbe. 23(6), 832-+.
- (2016). Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway. World Journal of Hepatology. 8(19), 796-814.
- (2016). Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. AIDS RESEARCH AND HUMAN RETROVIRUSES. 32(12), 1187-1197.
- (2015). Finding fusin/CXCR4, the first "2nd receptor" for HIV entry. Frontiers in Immunology. 6,
- (2015). Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. JOURNAL OF VIROLOGY. 89(13), 6685-6694.
- (2015). Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Current Opinion in HIV and AIDS. 10(3), 207-213.
- (2014). Efficient Infection of a Human B Cell Line with Cell-Free Kaposi's Sarcoma-Associated Herpesvirus. JOURNAL OF VIROLOGY. 88(3), 1748-1757.
- (2014). Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. PLoS Pathogens. 10(1),
- (2013). Blocking HIV-1 gp120 at the Phe43 Cavity: If the Extension Fits .... STRUCTURE. 21(6), 871-872.
- (2011). A New Model to Produce Infectious Hepatitis C Virus without the Replication Requirement. PLoS Pathogens. 7(4),
- (2011). An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection. ANTIVIRAL RESEARCH. 90(3), 143-150.
- (2011). HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor. JOURNAL OF IMMUNOLOGY. 186(11), 872-877.
- (2011). Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 108(50), 20148-20153.
- (2011). Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Current Opinion in HIV and AIDS. 6(1), 80-85.
- (2010). Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs. PLoS Pathogens. 6(6),
- (2007). HIV coreceptors: From discovery and designation to new paradigms and promise. EUROPEAN JOURNAL OF MEDICAL RESEARCH. 12(9), 375-384.
- (2007). HIV gp120 interactions with coreceptors: Insights from studies with CCR5-based peptides. EUROPEAN JOURNAL OF MEDICAL RESEARCH. 12(9), 403-407.
- (2006). Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. JOURNAL OF LEUKOCYTE BIOLOGY. 80(5), 1175-1182.
- (2006). Broad target cell selectivity of Kaposi's sarcoma-associated herpesvirus glycoprotein-mediated cell fusion and virion entry. VIROLOGY. 354(1), 7-14.
- (2006). Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: Cystine transporter xCT. SCIENCE. 311(5769), 1921-1924.
- (2005). An anti-HIV microbicide comes alive. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 102(35), 12294-12295.
- (2005). CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. GLIA. 52(3), 252-258.
- (2004). Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. BLOOD. 103(4), 1211-1217.
- (2003). Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46. JOURNAL OF BIOLOGICAL CHEMISTRY. 278(28), 25964-25969.
- (2003). Molecular characterization, reactivation, and depletion of latent HIV. IMMUNITY. 19(3), 413-423.
- (2003). Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. JOURNAL OF VIROLOGY. 77(5), 2859-2865.
- (2002). HIV's response to a CCR5 inhibitor: I'd rather tighten than switch! Commentary. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 99(4), 1749-1751.
- (2002). Human herpesvirus 6 and measles virus employ distinct CD46 domains for receptor function. JOURNAL OF BIOLOGICAL CHEMISTRY. 277(42), 39112-39118.
- (2002). Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. JOURNAL OF BIOLOGICAL CHEMISTRY. 277(37), 34383-34390.
- (2001). A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression. JOURNAL OF INFECTIOUS DISEASES. 183(11), 1592-1600.
- (2000). Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. JOURNAL OF INFECTIOUS DISEASES. 181(3), 921-926.
- (2000). Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 97(23), 12794-12799.
- (2000). Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. JOURNAL OF VIROLOGY. 74(10), 4562-4569.
- (1999). CD46 is a cellular receptor for human herpesvirus 6. CELL. 99(7), 817-827.
- (1999). Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annual Review of Immunology. 17, 657-700.
- (1998). A new classification for HIV-1. NATURE. 391(6664), 240-240.
- (1998). AIDS vaccine development. SCIENCE. 280(5365), 803-+.
- (1998). And the Best Picture is - the HIV gp120 envelope, please!. 5(8), 671-674.
- (1998). CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells. JOURNAL OF IMMUNOLOGY. 160(3), 1385-1392.
- (1998). HIV entry and tropism - When one receptor is not enough. Advances in Experimental Medicine and Biology. 452, 151-157.